parkinson's disease triple agonist glp-1 gip glucagon clinical trial Glucagon-like peptide-1 receptor agonists in movement disorders: From to the broader spectrum — Mechanisms, evidence, and future directions Beyond insulin: The Intriguing role

Originally developed for Type 2 diabetes, it has proven effective for weight loss, leading to its approval for obesity management under the brand names Wegovy and Ozempic

What they did: A two-phase study, first in a dish with human endothelial cells (HUVECs), then in a live rat with an ischemic limb (= they closed off the artery so that no blood reached the leg)

Findings enhance understanding of ASO interventions in neurological disorders

Wong W.-T

Neurological Alliance We want to raise awareness among medical professionals of this serious aspect of Pernicious Anaemia and so we are pleased to announce that we are now members of the Neurological Alliance an alliance of over 80 professional and patient support groups that are concerned with diseases of the nervous system

For example, a study might run for 4-6 weeks, followed by a 2-week washout period